Current therapeutic options for MPN include hydroxyurea, pegylated interferon alpha or the JAK1/2 inhibitor ruxolitinib which aim to reduce disease related symptoms such as splenomegaly and thromboembolic complications but are rarely curative, as they show little efficacy at antagonizing the natural course of the disease. This evidence concerns the gene JAK1 and myeloproliferative neoplasm.